
Stryker (SYK) Stock
Stryker Chart
Company Profile
Price: $395.20
Market Cap: $150.66B
Exchange: NYSE
CEO: Mr. Kevin A. Lobo
Sector: Healthcare
Industry: Medical - Devices
Employees: 52.00K
Headquarters: Kalamazoo, MI
Website: Stryker
Business Summary
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Stryker News
Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript
Stryker Corporation (NYSE:SYK ) Q4 2024 Earnings Conference Call January 28, 2025 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Andy Pierce - Group President of MedSurg & Neurotechnology Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Matthew O'Brien - Piper Sandler Companies Shagun Singh - RBC Matthew Miksic - Barclays Michael Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Josh Jennings - TD Cowen Danielle Antalffy - UBS Equities Michael Polark - Wolfe Research Operator Welcome to the Fourth Quarter 2024 Stryker Earnings Call. My name is Luke, and I'll be your operator for today's call.

Stryker (SYK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.

Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025.

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive with a PEG ratio around 3, but the company's consistent performance and market leadership justify a premium valuation. Stryker's strong company culture, impressive ROIC, and substantial insider ownership indicate a durable competitive advantage and a bright future.

Stryker (SYK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Beyond analysts' top -and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.
Portage, Michigan, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) today announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, Inc., a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2025, among Stryker, Eagle 1 Merger Sub, Inc and Inari.

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c.

Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari's innovative product portfolio is highly complementary to Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.

Stryker Earnings
This section highlights Stryker's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-01-28 | $3.87 | $4.01 |
Read Transcript | Q3 | 2024 | 2024-10-29 | $2.77 | $2.87 |
Read Transcript | Q2 | 2024 | 2024-07-30 | $2.79 | $2.81 |
Read Transcript | Q1 | 2024 | 2024-04-30 | $2.35 | $2.50 |
Read Transcript | Q4 | 2023 | 2024-01-30 | $3.27 | $3.46 |
Read Transcript | Q3 | 2023 | 2023-11-02 | $2.44 | $2.46 |
Read Transcript | Q2 | 2023 | 2023-08-03 | $2.38 | $2.54 |
Read Transcript | Q1 | 2023 | 2023-05-01 | $2.00 | $2.14 |
Financial Statements
Access annual & quarterly financial statements for Stryker, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $20.50B | $18.45B | $17.11B | $14.35B | $14.88B |
Cost of Revenue | $7.40B | $6.87B | $6.14B | $5.29B | $5.19B |
Gross Profit | $13.10B | $11.58B | $10.97B | $9.06B | $9.70B |
Gross Profit Ratio | 63.89% | 62.76% | 64.11% | 63.11% | 65.14% |
Research and Development Expenses | $1.39B | $1.45B | $1.24B | $984.00M | $971.00M |
General and Administrative Expenses | $- | $- | $- | $- | $- |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $6.92B | $6.46B | $6.43B | $5.36B | $5.36B |
Other Expenses | $901.00M | $627.00M | $619.00M | $472.00M | $464.00M |
Operating Expenses | $9.21B | $8.54B | $8.28B | $6.82B | $6.79B |
Cost and Expenses | $16.61B | $15.41B | $14.42B | $12.11B | $11.98B |
Interest Income | $75.00M | $94.00M | $68.00M | $102.00M | $155.00M |
Interest Expense | $356.00M | $158.00M | $337.00M | $315.00M | $287.00M |
Depreciation and Amortization | $1.03B | $998.00M | $990.00M | $812.00M | $778.00M |
EBITDA | $4.93B | $4.54B | $4.65B | $3.75B | $4.18B |
EBITDA Ratio | 24.07% | 22.99% | 22.09% | 21.39% | 26.03% |
Operating Income | $3.89B | $2.84B | $2.58B | $2.22B | $2.71B |
Operating Income Ratio | 18.97% | 15.40% | 15.10% | 15.49% | 18.23% |
Total Other Income Expenses Net | $-215.00M | $-158.00M | $-303.00M | $-269.00M | $-151.00M |
Income Before Tax | $3.67B | $2.68B | $2.28B | $1.95B | $2.56B |
Income Before Tax Ratio | 17.92% | 14.54% | 13.33% | 13.62% | 17.21% |
Income Tax Expense | $508.00M | $325.00M | $287.00M | $355.00M | $479.00M |
Net Income | $3.17B | $2.36B | $1.99B | $1.60B | $2.08B |
Net Income Ratio | 15.44% | 12.78% | 11.66% | 11.14% | 13.99% |
EPS | $8.34 | $6.23 | $5.29 | $4.26 | $5.57 |
EPS Diluted | $8.25 | $6.17 | $5.22 | $4.20 | $5.48 |
Weighted Average Shares Outstanding | 379.60M | 378.20M | 377.00M | 375.50M | 374.00M |
Weighted Average Shares Outstanding Diluted | 383.70M | 382.20M | 382.30M | 380.30M | 379.90M |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $6.44B | $5.49B | $5.42B | $5.24B | $5.82B | $4.91B | $5.00B | $4.78B | $5.20B | $4.48B | $4.49B | $4.28B | $4.70B | $4.16B | $4.29B | $3.95B | $4.26B | $3.74B | $2.76B | $3.59B |
Cost of Revenue | $2.26B | $1.98B | $2.10B | $2.06B | $2.11B | $1.75B | $1.81B | $1.76B | $1.97B | $1.70B | $1.67B | $1.54B | $1.66B | $1.52B | $1.52B | $1.44B | $1.54B | $1.28B | $1.22B | $1.26B |
Gross Profit | $4.17B | $3.52B | $3.32B | $3.18B | $3.70B | $3.16B | $3.18B | $3.02B | $3.24B | $2.78B | $2.83B | $2.73B | $3.04B | $2.64B | $2.77B | $2.51B | $2.72B | $2.46B | $1.55B | $2.33B |
Gross Profit Ratio | 64.85% | 64.02% | 61.31% | 60.73% | 63.68% | 64.33% | 63.67% | 63.12% | 62.21% | 62.11% | 62.90% | 63.95% | 64.77% | 63.51% | 64.56% | 63.47% | 63.75% | 65.85% | 56.01% | 64.97% |
Research and Development Expenses | $358.00M | $377.00M | $352.00M | $368.00M | $350.00M | $353.00M | $346.00M | $339.00M | $326.00M | $364.00M | $351.00M | $413.00M | $331.00M | $306.00M | $310.00M | $288.00M | $255.00M | $242.00M | $233.00M | $254.00M |
General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.23B | $1.33B |
Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $2.12B | $1.90B | $1.81B | $1.84B | $1.94B | $1.70B | $1.71B | $1.78B | $1.75B | $1.46B | $1.54B | $1.71B | $1.75B | $1.60B | $1.50B | $1.57B | $1.56B | $1.24B | $1.23B | $1.33B |
Other Expenses | $- | $159.00M | $-53.00M | $-49.00M | $-31.00M | $-62.00M | $-66.00M | $161.00M | $158.00M | $159.00M | $160.00M | $150.00M | $-62.00M | $-79.00M | $-70.00M | $-92.00M | $-78.00M | $-79.00M | $-67.00M | $-45.00M |
Operating Expenses | $2.48B | $2.43B | $2.17B | $2.21B | $2.44B | $2.22B | $2.21B | $2.28B | $2.23B | $1.98B | $2.05B | $2.27B | $2.22B | $2.05B | $1.96B | $2.04B | $1.95B | $1.60B | $1.57B | $1.70B |
Cost and Expenses | $4.74B | $4.41B | $4.26B | $4.27B | $4.55B | $3.97B | $4.03B | $4.04B | $4.20B | $3.67B | $3.72B | $3.81B | $3.88B | $3.57B | $3.49B | $3.49B | $3.49B | $2.88B | $2.78B | $2.96B |
Interest Income | $- | $- | $- | $- | $35.00M | $15.00M | $11.00M | $14.00M | $33.00M | $26.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Interest Expense | $- | $- | $- | $- | $- | $- | $- | $56.00M | $53.00M | $- | $52.00M | $61.00M | $- | $- | $- | $- | $- | $- | $- | $- |
Depreciation and Amortization | $- | $268.00M | $258.00M | $260.00M | $250.00M | $262.00M | $259.00M | $257.00M | $253.00M | $250.00M | $253.00M | $242.00M | $238.00M | $235.00M | $241.00M | $276.00M | $223.00M | $198.00M | $193.00M | $198.00M |
EBITDA | $581.00M | $1.35B | $1.31B | $1.23B | $1.59B | $1.19B | $1.22B | $992.00M | $1.42B | $1.03B | $1.13B | $927.00M | $1.34B | $1.12B | $1.18B | $999.00M | $1.33B | $1.11B | $173.00M | $914.00M |
EBITDA Ratio | 9.03% | 24.63% | 26.12% | 23.57% | 26.12% | 24.67% | 24.62% | 20.76% | 27.70% | 23.44% | 22.99% | 16.77% | 22.70% | 20.22% | 26.20% | 18.90% | 23.79% | 28.39% | 6.26% | 22.88% |
Operating Income | $581.00M | $1.08B | $1.16B | $976.00M | $1.26B | $931.00M | $965.00M | $735.00M | $1.19B | $808.00M | $772.00M | $447.00M | $819.00M | $574.00M | $732.00M | $459.00M | $749.00M | $859.00M | $-20.00M | $635.00M |
Operating Income Ratio | 9.03% | 19.75% | 21.36% | 18.62% | 21.62% | 18.97% | 19.32% | 15.38% | 22.84% | 18.04% | 17.18% | 10.46% | 17.42% | 13.80% | 17.05% | 11.61% | 17.57% | 22.99% | -0.72% | 17.70% |
Total Other Income Expenses Net | $-53.00M | $-42.00M | $-53.00M | $-49.00M | $-31.00M | $-62.00M | $-66.00M | $-56.00M | $-53.00M | $8.00M | $-52.00M | $-61.00M | $-62.00M | $-79.00M | $-70.00M | $-92.00M | $-78.00M | $-79.00M | $-67.00M | $-45.00M |
Income Before Tax | $528.00M | $1.04B | $998.00M | $923.00M | $1.23B | $869.00M | $899.00M | $679.00M | $761.00M | $816.00M | $720.00M | $386.00M | $757.00M | $495.00M | $662.00M | $367.00M | $671.00M | $780.00M | $-87.00M | $590.00M |
Income Before Tax Ratio | 8.20% | 18.98% | 18.41% | 17.60% | 21.08% | 17.70% | 17.99% | 14.21% | 14.63% | 18.22% | 16.02% | 9.03% | 16.10% | 11.90% | 15.42% | 9.28% | 15.74% | 20.87% | -3.15% | 16.44% |
Income Tax Expense | $-18.00M | $209.00M | $173.00M | $135.00M | $83.00M | $177.00M | $161.00M | $87.00M | $198.00M | $-8.00M | $64.00M | $63.00M | $95.00M | $57.00M | $70.00M | $65.00M | $103.00M | $159.00M | $-4.00M | $97.00M |
Net Income | $546.00M | $834.00M | $825.00M | $788.00M | $1.14B | $692.00M | $738.00M | $592.00M | $563.00M | $816.00M | $656.00M | $323.00M | $662.00M | $438.00M | $592.00M | $302.00M | $568.00M | $621.00M | $-83.00M | $493.00M |
Net Income Ratio | 8.48% | 15.18% | 15.22% | 15.03% | 19.66% | 14.10% | 14.77% | 12.39% | 10.82% | 18.22% | 14.60% | 7.56% | 14.08% | 10.53% | 13.79% | 7.64% | 13.33% | 16.62% | -3.00% | 13.74% |
EPS | $1.43 | $2.19 | $2.17 | $2.07 | $3.01 | $1.82 | $1.94 | $1.56 | $1.49 | $2.16 | $1.73 | $0.86 | $1.75 | $1.17 | $1.57 | $0.80 | $1.51 | $1.66 | $-0.22 | $1.32 |
EPS Diluted | $1.41 | $2.16 | $2.14 | $2.05 | $2.98 | $1.80 | $1.92 | $1.54 | $1.47 | $2.14 | $1.72 | $0.84 | $1.73 | $1.14 | $1.55 | $0.79 | $1.49 | $1.63 | $-0.22 | $1.30 |
Weighted Average Shares Outstanding | 381.30M | 381.10M | 381.00M | 380.40M | 380.00M | 379.80M | 379.70M | 379.00M | 378.50M | 378.40M | 378.30M | 377.70M | 377.30M | 377.10M | 376.90M | 376.30M | 375.90M | 375.70M | 375.50M | 374.80M |
Weighted Average Shares Outstanding Diluted | 386.10M | 385.60M | 385.40M | 385.10M | 383.90M | 384.00M | 383.90M | 383.20M | 382.30M | 381.80M | 382.20M | 382.70M | 382.70M | 382.70M | 382.30M | 381.70M | 381.30M | 380.20M | 375.50M | 379.70M |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $2.97B | $1.84B | $2.94B | $2.94B | $4.34B |
Short Term Investments | $82.00M | $84.00M | $75.00M | $81.00M | $88.00M |
Cash and Short Term Investments | $3.05B | $1.93B | $3.02B | $3.02B | $4.42B |
Net Receivables | $3.77B | $3.56B | $3.02B | $2.70B | $2.89B |
Inventory | $4.84B | $4.00B | $3.31B | $3.49B | $3.28B |
Other Current Assets | $857.00M | $1.54B | $1.18B | $960.00M | $1.33B |
Total Current Assets | $12.52B | $10.28B | $10.02B | $9.71B | $11.36B |
Property Plant Equipment Net | $3.21B | $2.97B | $2.83B | $2.75B | $2.57B |
Goodwill | $15.24B | $14.88B | $12.92B | $12.78B | $9.07B |
Intangible Assets | $4.59B | $4.88B | $4.84B | $5.55B | $4.23B |
Goodwill and Intangible Assets | $19.84B | $19.77B | $17.76B | $18.33B | $13.30B |
Long Term Investments | $496.00M | $90.00M | $66.00M | $4.00M | $- |
Tax Assets | $1.67B | $1.41B | $1.76B | $1.53B | $1.57B |
Other Non-Current Assets | $2.67B | $2.37B | $2.20B | $2.00B | $1.37B |
Total Non-Current Assets | $27.39B | $26.61B | $24.61B | $24.62B | $18.81B |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $39.91B | $36.88B | $34.63B | $34.33B | $30.17B |
Account Payables | $1.52B | $1.41B | $1.13B | $810.00M | $675.00M |
Short Term Debt | $2.24B | $1.31B | $119.00M | $870.00M | $945.00M |
Tax Payables | $391.00M | $292.00M | $192.00M | $207.00M | $171.00M |
Deferred Revenue | $- | $- | $- | $- | $- |
Other Current Liabilities | $3.78B | $3.29B | $3.11B | $3.15B | $2.61B |
Total Current Liabilities | $7.92B | $6.30B | $4.55B | $5.04B | $4.40B |
Long Term Debt | $11.26B | $12.21B | $12.78B | $13.55B | $10.53B |
Deferred Revenue Non-Current | $- | $-67.00M | $-68.00M | $-117.00M | $-108.00M |
Deferred Tax Liabilities Non-Current | $- | $67.00M | $68.00M | $117.00M | $108.00M |
Other Non-Current Liabilities | $2.14B | $1.75B | $2.42B | $2.65B | $2.43B |
Total Non-Current Liabilities | $13.40B | $13.96B | $15.21B | $16.20B | $12.96B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $21.32B | $20.27B | $19.75B | $21.25B | $17.36B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $38.00M | $38.00M | $38.00M | $38.00M | $37.00M |
Retained Earnings | $16.77B | $14.77B | $13.48B | $12.46B | $11.75B |
Accumulated Other Comprehensive Income Loss | $-416.00M | $-221.00M | $-531.00M | $-1.16B | $-606.00M |
Other Total Stockholders Equity | $2.20B | $2.03B | $1.89B | $1.74B | $1.63B |
Total Stockholders Equity | $18.59B | $16.62B | $14.88B | $13.08B | $12.81B |
Total Equity | $18.59B | $16.62B | $14.88B | $13.08B | $12.81B |
Total Liabilities and Stockholders Equity | $39.91B | $36.88B | $34.63B | $34.33B | $30.17B |
Minority Interest | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $39.91B | $36.88B | $34.63B | $34.33B | $30.17B |
Total Investments | $82.00M | $84.00M | $75.00M | $81.00M | $88.00M |
Total Debt | $12.99B | $13.05B | $12.47B | $13.23B | $10.23B |
Net Debt | $10.02B | $11.20B | $9.53B | $10.29B | $5.89B |
Balance Sheet Charts
Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $3.65B | $3.85B | $1.87B | $2.33B | $2.97B | $1.86B | $1.40B | $1.67B | $1.84B | $1.42B | $1.04B | $1.46B | $2.94B | $2.56B | $2.24B | $2.24B | $2.94B | $7.08B | $6.54B | $3.96B |
Short Term Investments | $750.00M | $834.00M | $83.00M | $77.00M | $82.00M | $76.00M | $77.00M | $86.00M | $84.00M | $77.00M | $83.00M | $72.00M | $75.00M | $76.00M | $84.00M | $74.00M | $81.00M | $78.00M | $80.00M | $84.00M |
Cash and Short Term Investments | $4.40B | $4.68B | $1.96B | $2.41B | $3.05B | $1.94B | $1.48B | $1.76B | $1.93B | $1.50B | $1.13B | $1.53B | $3.02B | $2.64B | $2.33B | $2.31B | $3.02B | $7.16B | $6.62B | $4.05B |
Net Receivables | $3.99B | $3.74B | $3.62B | $3.47B | $3.77B | $3.28B | $3.26B | $3.21B | $3.56B | $3.10B | $3.15B | $2.99B | $3.02B | $2.82B | $2.71B | $2.62B | $2.70B | $2.43B | $2.20B | $2.65B |
Inventory | $4.77B | $5.29B | $5.04B | $5.03B | $4.84B | $4.88B | $4.59B | $4.33B | $4.00B | $3.88B | $3.75B | $3.52B | $3.31B | $3.43B | $3.43B | $3.47B | $3.49B | $3.46B | $3.44B | $3.36B |
Other Current Assets | $1.68B | $961.00M | $1.02B | $986.00M | $857.00M | $950.00M | $819.00M | $850.00M | $1.54B | $1.49B | $1.41B | $1.26B | $1.18B | $1.07B | $1.07B | $1.06B | $960.00M | $975.00M | $1.05B | $1.24B |
Total Current Assets | $14.85B | $14.67B | $11.64B | $11.89B | $12.52B | $11.04B | $10.15B | $10.15B | $10.28B | $9.32B | $8.82B | $8.72B | $10.02B | $9.46B | $9.03B | $8.98B | $9.71B | $13.54B | $12.80B | $10.74B |
Property Plant Equipment Net | $3.45B | $3.94B | $3.83B | $3.26B | $3.21B | $3.11B | $3.08B | $3.04B | $2.97B | $2.80B | $2.80B | $2.79B | $2.83B | $2.75B | $2.74B | $2.71B | $2.75B | $2.53B | $2.53B | $2.61B |
Goodwill | $- | $16.40B | $15.41B | $15.35B | $15.24B | $15.14B | $15.17B | $14.85B | $14.88B | $14.99B | $15.12B | $15.23B | $12.92B | $12.89B | $12.80B | $12.80B | $12.78B | $9.13B | $9.07B | $9.03B |
Intangible Assets | $- | $4.94B | $4.36B | $4.51B | $4.59B | $4.73B | $4.92B | $4.78B | $4.88B | $5.05B | $5.25B | $5.43B | $4.84B | $5.06B | $5.26B | $5.38B | $5.55B | $3.92B | $4.01B | $4.11B |
Goodwill and Intangible Assets | $20.25B | $21.34B | $19.77B | $19.86B | $19.84B | $19.87B | $20.09B | $19.63B | $19.77B | $20.05B | $20.36B | $20.66B | $17.76B | $17.95B | $18.06B | $18.18B | $18.33B | $13.04B | $13.09B | $13.13B |
Long Term Investments | $- | $- | $16.00M | $146.00M | $2.00M | $12.00M | $135.00M | $79.00M | $90.00M | $- | $152.00M | $75.00M | $66.00M | $38.00M | $23.00M | $- | $- | $- | $- | $- |
Tax Assets | $1.74B | $1.56B | $1.61B | $1.64B | $1.67B | $1.41B | $1.44B | $1.44B | $1.41B | $1.39B | $1.62B | $1.60B | $1.76B | $1.86B | $1.75B | $1.52B | $1.53B | $1.63B | $1.57B | $1.54B |
Other Non-Current Assets | $2.68B | $2.32B | $2.26B | $2.60B | $2.67B | $2.60B | $2.51B | $2.49B | $2.37B | $2.43B | $2.27B | $2.28B | $2.20B | $2.09B | $2.09B | $2.07B | $2.01B | $1.54B | $1.50B | $1.43B |
Total Non-Current Assets | $28.12B | $29.16B | $27.48B | $27.51B | $27.39B | $27.00B | $27.26B | $26.68B | $26.61B | $26.66B | $27.21B | $27.41B | $24.61B | $24.68B | $24.67B | $24.48B | $24.62B | $18.74B | $18.68B | $18.70B |
Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $42.97B | $43.83B | $39.13B | $39.40B | $39.91B | $38.04B | $37.41B | $36.83B | $36.88B | $35.98B | $36.03B | $36.14B | $34.63B | $34.15B | $33.70B | $33.45B | $34.33B | $32.29B | $31.48B | $29.44B |
Account Payables | $- | $1.34B | $1.30B | $1.25B | $1.52B | $1.30B | $1.33B | $1.37B | $1.41B | $1.21B | $1.16B | $1.08B | $1.13B | $934.00M | $864.00M | $767.00M | $810.00M | $647.00M | $635.00M | $736.00M |
Short Term Debt | $12.19B | $2.16B | $2.24B | $2.21B | $2.24B | $2.44B | $1.92B | $1.34B | $1.31B | $124.00M | $125.00M | $343.00M | $119.00M | $130.00M | $115.00M | $124.00M | $870.00M | $1.22B | $1.20B | $1.19B |
Tax Payables | $349.00M | $394.00M | $334.00M | $444.00M | $391.00M | $465.00M | $469.00M | $371.00M | $292.00M | $243.00M | $300.00M | $173.00M | $192.00M | $373.00M | $300.00M | $253.00M | $207.00M | $261.00M | $214.00M | $227.00M |
Deferred Revenue | $- | $- | $-11.43B | $-1.25B | $7.32B | $-1.30B | $-1.33B | $- | $1.41B | $1.39B | $1.62B | $- | $- | $373.00M | $300.00M | $253.00M | $207.00M | $261.00M | $214.00M | $227.00M |
Other Current Liabilities | $-4.92B | $3.78B | $3.05B | $3.05B | $3.78B | $3.26B | $2.87B | $2.79B | $3.29B | $2.99B | $2.82B | $2.81B | $3.11B | $3.01B | $2.97B | $2.81B | $3.15B | $2.56B | $2.35B | $2.01B |
Total Current Liabilities | $7.62B | $7.67B | $6.93B | $6.96B | $7.92B | $7.46B | $6.58B | $5.87B | $6.30B | $4.57B | $4.40B | $4.41B | $4.55B | $4.45B | $4.25B | $3.95B | $5.04B | $4.69B | $4.41B | $4.16B |
Long Term Debt | $- | $13.32B | $10.51B | $11.19B | $11.26B | $10.75B | $11.51B | $12.22B | $12.21B | $13.10B | $13.73B | $14.26B | $12.78B | $12.93B | $13.04B | $13.38B | $13.55B | $12.32B | $12.13B | $9.71B |
Deferred Revenue Non-Current | $- | $- | $- | $- | $-63.00M | $- | $- | $- | $-67.00M | $- | $- | $- | $-847.00M | $-931.00M | $- | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $63.00M | $- | $- | $- | $67.00M | $1.39B | $1.62B | $1.60B | $1.76B | $1.86B | $- | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $- | $2.69B | $1.94B | $2.09B | $2.14B | $1.93B | $1.95B | $1.84B | $1.75B | $1.85B | $2.23B | $2.43B | $2.42B | $2.59B | $2.59B | $2.62B | $2.65B | $2.29B | $2.19B | $2.45B |
Total Non-Current Liabilities | $- | $16.02B | $12.44B | $13.28B | $13.40B | $12.68B | $13.46B | $14.07B | $13.96B | $14.95B | $15.95B | $16.68B | $15.21B | $15.52B | $15.63B | $16.00B | $16.20B | $14.61B | $14.32B | $12.16B |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $- | $23.68B | $19.37B | $20.23B | $21.32B | $20.14B | $20.05B | $19.93B | $20.27B | $19.52B | $20.36B | $21.09B | $19.75B | $19.97B | $19.88B | $19.95B | $21.25B | $19.30B | $18.73B | $16.32B |
Preferred Stock | $- | $- | $- | $19.13B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $- | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M | $38.00M |
Retained Earnings | $- | $18.30B | $17.77B | $17.25B | $16.77B | $15.93B | $15.53B | $15.07B | $14.77B | $14.49B | $13.93B | $13.54B | $13.48B | $13.08B | $12.88B | $12.53B | $12.46B | $12.13B | $11.72B | $12.02B |
Accumulated Other Comprehensive Income Loss | $- | $-545.00M | $-355.00M | $-377.00M | $-416.00M | $-249.00M | $-330.00M | $-305.00M | $-221.00M | $-89.00M | $-286.00M | $-479.00M | $-531.00M | $-816.00M | $-943.00M | $-867.00M | $-1.16B | $-917.00M | $-715.00M | $-623.00M |
Other Total Stockholders Equity | $42.97B | $2.35B | $2.31B | $2.26B | $2.20B | $2.18B | $2.13B | $2.09B | $2.03B | $2.03B | $1.99B | $1.95B | $1.89B | $1.88B | $1.84B | $1.81B | $1.74B | $1.74B | $1.71B | $1.68B |
Total Stockholders Equity | $42.97B | $20.15B | $19.76B | $19.17B | $18.59B | $17.91B | $17.36B | $16.89B | $16.62B | $16.46B | $15.67B | $15.05B | $14.88B | $14.18B | $13.82B | $13.50B | $13.08B | $12.99B | $12.75B | $13.12B |
Total Equity | $42.97B | $20.15B | $19.76B | $19.17B | $18.59B | $17.91B | $17.36B | $16.89B | $16.62B | $16.46B | $15.67B | $15.05B | $14.88B | $14.18B | $13.82B | $13.50B | $13.08B | $12.99B | $12.75B | $13.12B |
Total Liabilities and Stockholders Equity | $42.97B | $43.83B | $39.13B | $39.40B | $39.91B | $38.04B | $37.41B | $36.83B | $36.88B | $35.98B | $36.03B | $36.14B | $34.63B | $34.15B | $33.70B | $33.45B | $34.33B | $32.29B | $31.48B | $29.44B |
Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $42.97B | $43.83B | $39.13B | $39.40B | $39.91B | $38.04B | $37.41B | $36.83B | $36.88B | $35.98B | $36.03B | $36.14B | $34.63B | $34.15B | $33.70B | $33.45B | $34.33B | $32.29B | $31.48B | $29.44B |
Total Investments | $750.00M | $834.00M | $99.00M | $77.00M | $82.00M | $76.00M | $77.00M | $86.00M | $84.00M | $77.00M | $83.00M | $72.00M | $75.00M | $76.00M | $84.00M | $74.00M | $81.00M | $78.00M | $80.00M | $84.00M |
Total Debt | $12.19B | $15.48B | $12.74B | $10.81B | $12.99B | $10.38B | $11.15B | $11.86B | $13.05B | $12.75B | $13.37B | $14.10B | $12.47B | $12.63B | $12.73B | $13.06B | $13.23B | $12.01B | $11.81B | $9.40B |
Net Debt | $8.54B | $11.63B | $10.87B | $8.48B | $10.02B | $8.52B | $9.75B | $10.19B | $11.20B | $11.33B | $12.33B | $12.64B | $9.53B | $10.07B | $10.49B | $10.82B | $10.29B | $4.92B | $5.27B | $5.44B |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $3.17B | $2.36B | $1.99B | $1.60B | $2.08B |
Depreciation and Amortization | $1.03B | $998.00M | $990.00M | $812.00M | $778.00M |
Deferred Income Tax | $-206.00M | $58.00M | $-237.00M | $48.00M | $126.00M |
Stock Based Compensation | $205.00M | $168.00M | $171.00M | $142.00M | $127.00M |
Change in Working Capital | $-500.00M | $-732.00M | $279.00M | $866.00M | $-670.00M |
Accounts Receivables | $-175.00M | $-579.00M | $-377.00M | $354.00M | $-563.00M |
Inventory | $-797.00M | $-762.00M | $-189.00M | $27.00M | $-400.00M |
Accounts Payables | $77.00M | $290.00M | $329.00M | $100.00M | $63.00M |
Other Working Capital | $395.00M | $319.00M | $516.00M | $385.00M | $230.00M |
Other Non Cash Items | $19.00M | $-226.00M | $66.00M | $-190.00M | $-253.00M |
Net Cash Provided by Operating Activities | $3.71B | $2.62B | $3.26B | $3.28B | $2.19B |
Investments in Property Plant and Equipment | $-575.00M | $-588.00M | $-525.00M | $-487.00M | $-649.00M |
Acquisitions Net | $-390.00M | $-2.56B | $-339.00M | $-4.22B | $-802.00M |
Purchases of Investments | $-52.00M | $-52.00M | $-49.00M | $-54.00M | $-74.00M |
Sales Maturities of Investments | $54.00M | $240.00M | $55.00M | $61.00M | $69.00M |
Other Investing Activities | $1.00M | $39.00M | $-1.00M | $1.00M | $1.00M |
Net Cash Used for Investing Activities | $-962.00M | $-2.92B | $-859.00M | $-4.70B | $-1.46B |
Debt Repayment | $-277.00M | $472.00M | $-1.15B | $989.00M | $1.29B |
Common Stock Issued | $- | $- | $114.00M | $- | $- |
Common Stock Repurchased | $-155.00M | $-122.00M | $-114.00M | $-110.00M | $-307.00M |
Dividends Paid | $-1.14B | $-1.05B | $-950.00M | $-863.00M | $-778.00M |
Other Financing Activities | $-178.00M | $-170.00M | $-269.00M | $-27.00M | $-205.00M |
Net Cash Used Provided by Financing Activities | $-1.59B | $-749.00M | $-2.37B | $-11.00M | $3.00M |
Effect of Forex Changes on Cash | $-28.00M | $-51.00M | $-38.00M | $41.00M | $-18.00M |
Net Change in Cash | $1.13B | $-1.10B | $1.00M | $-1.39B | $721.00M |
Cash at End of Period | $2.97B | $1.84B | $2.94B | $2.94B | $4.34B |
Cash at Beginning of Period | $1.84B | $2.94B | $2.94B | $4.34B | $3.62B |
Operating Cash Flow | $3.71B | $2.62B | $3.26B | $3.28B | $2.19B |
Capital Expenditure | $-575.00M | $-588.00M | $-525.00M | $-487.00M | $-649.00M |
Free Cash Flow | $3.14B | $2.04B | $2.74B | $2.79B | $1.54B |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $834.00M | $825.00M | $788.00M | $1.14B | $692.00M | $738.00M | $592.00M | $563.00M | $816.00M | $656.00M | $323.00M | $662.00M | $438.00M | $592.00M | $302.00M | $568.00M | $621.00M | $-83.00M | $493.00M | $725.00M |
Depreciation and Amortization | $268.00M | $258.00M | $260.00M | $250.00M | $262.00M | $259.00M | $257.00M | $253.00M | $250.00M | $253.00M | $242.00M | $238.00M | $235.00M | $241.00M | $276.00M | $223.00M | $198.00M | $193.00M | $198.00M | $195.00M |
Deferred Income Tax | $10.00M | $8.00M | $-39.00M | $-182.00M | $- | $- | $-3.00M | $58.00M | $- | $- | $- | $-29.00M | $-127.00M | $-18.00M | $-145.00M | $-83.00M | $-30.00M | $-25.00M | $-52.00M | $-52.00M |
Stock Based Compensation | $51.00M | $46.00M | $87.00M | $40.00M | $52.00M | $39.00M | $74.00M | $28.00M | $33.00M | $36.00M | $71.00M | $30.00M | $34.00M | $39.00M | $68.00M | $27.00M | $29.00M | $30.00M | $56.00M | $32.00M |
Change in Working Capital | $280.00M | $-529.00M | $-844.00M | $278.00M | $192.00M | $-247.00M | $-404.00M | $187.00M | $-177.00M | $-380.00M | $-362.00M | $100.00M | $260.00M | $45.00M | $-126.00M | $446.00M | $10.00M | $510.00M | $-100.00M | $-185.00M |
Accounts Receivables | $-36.00M | $-155.00M | $258.00M | $-441.00M | $-42.00M | $-57.00M | $365.00M | $-393.00M | $-27.00M | $-212.00M | $53.00M | $-232.00M | $-121.00M | $-89.00M | $65.00M | $-113.00M | $-204.00M | $467.00M | $204.00M | $-439.00M |
Inventory | $-132.00M | $-46.00M | $-184.00M | $125.00M | $-333.00M | $-275.00M | $-314.00M | $-8.00M | $-231.00M | $-294.00M | $-229.00M | $42.00M | $-103.00M | $-55.00M | $-73.00M | $181.00M | $27.00M | $-59.00M | $-122.00M | $14.00M |
Accounts Payables | $2.00M | $52.00M | $-257.00M | $195.00M | $-21.00M | $-41.00M | $-56.00M | $179.00M | $77.00M | $86.00M | $-52.00M | $195.00M | $77.00M | $94.00M | $-37.00M | $126.00M | $8.00M | $-97.00M | $63.00M | $26.00M |
Other Working Capital | $446.00M | $-380.00M | $-844.00M | $399.00M | $588.00M | $126.00M | $-399.00M | $409.00M | $4.00M | $40.00M | $-134.00M | $95.00M | $407.00M | $95.00M | $-81.00M | $252.00M | $179.00M | $199.00M | $-245.00M | $214.00M |
Other Non Cash Items | $31.00M | $736.00M | $520.00M | $-1.00M | $-96.10M | $-62.20M | $-74.00M | $-86.00M | $-33.00M | $-36.00M | $-71.00M | $-1.00M | $93.00M | $-21.00M | $77.00M | $56.00M | $1.00M | $-5.00M | $-4.00M | $20.00M |
Net Cash Provided by Operating Activities | $1.47B | $633.00M | $204.00M | $1.53B | $1.05B | $688.00M | $445.00M | $1.00B | $889.00M | $529.00M | $203.00M | $1.00B | $933.00M | $878.00M | $452.00M | $1.24B | $829.00M | $620.00M | $591.00M | $735.00M |
Investments in Property Plant and Equipment | $-170.00M | $-152.00M | $-167.00M | $-145.00M | $-148.00M | $-152.00M | $-130.00M | $-188.00M | $-138.00M | $-143.00M | $-119.00M | $-206.00M | $-130.00M | $-106.00M | $-83.00M | $-165.00M | $-69.00M | $-109.00M | $-144.00M | $-199.00M |
Acquisitions Net | $-1.26B | $-88.00M | $-246.00M | $-246.00M | $-1.00M | $-390.00M | $- | $- | $- | $- | $-2.56B | $-113.00M | $-122.00M | $-77.00M | $-27.00M | $-4.20B | $- | $-3.00M | $-23.00M | $-521.00M |
Purchases of Investments | $-759.00M | $-14.00M | $-18.00M | $-11.00M | $-6.00M | $-7.00M | $-28.00M | $-9.00M | $-5.00M | $-29.00M | $-9.00M | $-11.00M | $-7.00M | $-26.00M | $-5.00M | $-20.00M | $-11.00M | $-15.00M | $-8.00M | $-17.00M |
Sales Maturities of Investments | $9.00M | $107.00M | $23.00M | $5.00M | $7.00M | $17.00M | $25.00M | $3.00M | $208.00M | $18.00M | $11.00M | $12.00M | $15.00M | $16.00M | $12.00M | $17.00M | $13.00M | $19.00M | $12.00M | $17.00M |
Other Investing Activities | $12.00M | $30.00M | $5.00M | $-1.00M | $3.00M | $-1.00M | $1.00M | $32.00M | $7.00M | $2.00M | $-2.00M | $4.00M | $-3.00M | $-9.00M | $7.00M | $12.00M | $-2.00M | $-9.00M | $4.00M | $1.00M |
Net Cash Used for Investing Activities | $-2.17B | $-117.00M | $-408.00M | $-152.00M | $-145.00M | $-533.00M | $-132.00M | $-162.00M | $72.00M | $-152.00M | $-2.68B | $-314.00M | $-247.00M | $-202.00M | $-96.00M | $-4.35B | $-69.00M | $-117.00M | $-163.00M | $-719.00M |
Debt Repayment | $2.98B | $-599.00M | $-1.00M | $35.00M | $-107.00M | $-103.00M | $-102.00M | $-150.00M | $-250.00M | $-458.00M | $1.33B | $- | $14.00M | $-410.00M | $-743.00M | $-807.00M | $-5.00M | $2.30B | $-496.00M | $2.64B |
Common Stock Issued | $- | $- | $- | $- | $- | $-2.00M | $- | $33.00M | $5.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock Repurchased | $- | $-14.00M | $-113.00M | $-34.00M | $-10.00M | $-17.00M | $-94.00M | $-33.00M | $-5.00M | $-12.00M | $-72.00M | $-26.00M | $-14.00M | $-21.00M | $-53.00M | $-31.00M | $-11.00M | $-12.00M | $-56.00M | $-6.00M |
Dividends Paid | $-305.00M | $-305.00M | $-304.00M | $-285.00M | $-285.00M | $-285.00M | $-284.00M | $-263.00M | $-263.00M | $-263.00M | $-262.00M | $-237.00M | $-238.00M | $-237.00M | $-238.00M | $-216.00M | $-216.00M | $-216.00M | $-215.00M | $-193.00M |
Other Financing Activities | $-20.00M | $-62.00M | $-113.00M | $-36.00M | $-30.00M | $-17.00M | $-95.00M | $-33.00M | $-30.00M | $-32.00M | $-75.00M | $-51.00M | $-124.00M | $-29.00M | $-72.00M | $-3.00M | $-21.00M | $-25.00M | $-57.00M | $-85.00M |
Net Cash Used Provided by Financing Activities | $2.65B | $-966.00M | $-418.00M | $-286.00M | $-422.00M | $-405.00M | $-481.00M | $-446.00M | $-543.00M | $-753.00M | $993.00M | $-288.00M | $-348.00M | $-676.00M | $-1.05B | $-1.06B | $-242.00M | $2.06B | $-768.00M | $2.36B |
Effect of Forex Changes on Cash | $21.00M | $-6.00M | $-19.00M | $21.00M | $-24.00M | $-20.00M | $-5.00M | $29.00M | $-42.00M | $-38.00M | $- | $-17.00M | $-16.00M | $3.00M | $-8.00M | $32.00M | $26.00M | $16.00M | $-33.00M | $10.00M |
Net Change in Cash | $1.98B | $-456.00M | $-641.00M | $1.11B | $-942.00M | $-1.94B | $-2.02B | $424.00M | $376.00M | $-414.00M | $-1.49B | $381.00M | $322.00M | $3.00M | $-705.00M | $-4.14B | $544.00M | $2.58B | $-373.00M | $2.69B |
Cash at End of Period | $3.85B | $1.87B | $2.33B | $2.97B | $459.00M | $-270.00M | $-173.00M | $1.84B | $1.42B | $1.04B | $1.46B | $2.94B | $2.56B | $2.24B | $2.24B | $2.94B | $7.08B | $6.54B | $3.96B | $4.34B |
Cash at Beginning of Period | $1.87B | $2.33B | $2.97B | $1.86B | $1.40B | $1.67B | $1.84B | $1.42B | $1.04B | $1.46B | $2.94B | $2.56B | $2.24B | $2.24B | $2.94B | $7.08B | $6.54B | $3.96B | $4.34B | $1.65B |
Operating Cash Flow | $1.47B | $633.00M | $204.00M | $1.53B | $1.05B | $688.00M | $445.00M | $1.00B | $889.00M | $529.00M | $203.00M | $1.00B | $933.00M | $878.00M | $452.00M | $1.24B | $829.00M | $620.00M | $591.00M | $735.00M |
Capital Expenditure | $-170.00M | $-152.00M | $-167.00M | $-145.00M | $-148.00M | $-152.00M | $-130.00M | $-188.00M | $-138.00M | $-143.00M | $-119.00M | $-206.00M | $-130.00M | $-106.00M | $-83.00M | $-165.00M | $-69.00M | $-109.00M | $-144.00M | $-199.00M |
Free Cash Flow | $1.30B | $481.00M | $37.00M | $1.38B | $902.00M | $536.00M | $315.00M | $815.00M | $751.00M | $386.00M | $84.00M | $794.00M | $803.00M | $772.00M | $369.00M | $1.07B | $760.00M | $511.00M | $447.00M | $536.00M |
Stryker Stock Forecast
Analyst ratings, price targets, and earnings estimates for SYK.
SYK Analyst Ratings
Strong Buy
Based on 19 analysts in the past 3 months
SYK Stock 12 Month Forecast
$434.67
Based on 3 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Feb 03, 2025 | David Toung | Argus Research | $450.00 | $391.14 | 15.0% |
Dec 18, 2024 | Richard Newitter | Truist Financial | $409.00 | $359.17 | 13.9% |
Dec 02, 2024 | Patrick Wood | Morgan Stanley | $445.00 | $390.90 | 13.8% |
Oct 31, 2024 | Joanne Wuensch | Citigroup | $411.00 | $363.43 | 13.1% |
Oct 30, 2024 | Matt O'Brien | Piper Sandler | $420.00 | $367.95 | 14.1% |
Oct 30, 2024 | Richard Newitter | Truist Financial | $380.00 | $365.42 | 4.0% |
Oct 30, 2024 | Kyle Rose | Canaccord Genuity | $400.00 | $359.01 | 11.4% |
Oct 30, 2024 | Ryan Zimmerman | BTIG | $394.00 | $359.01 | 9.7% |
Oct 14, 2024 | Richard Newitter | Truist Financial | $370.00 | $356.45 | 3.8% |
Sep 10, 2024 | Matt O\'Brien | Piper Sandler | $380.00 | $365.22 | 4.0% |
Stryker Dividends
Explore Stryker's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.00%
Dividend Payout Ratio
35.99%
Dividend Paid & Capex Coverage Ratio
2.17x
Stryker Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$0.84 | $0.84 | March 31, 2025 | March 31, 2025 | April 30, 2025 | February 05, 2025 |
$0.84 | $0.84 | December 31, 2024 | December 31, 2024 | January 31, 2025 | December 10, 2024 |
$0.8 | $0.8 | September 30, 2024 | September 30, 2024 | October 31, 2024 | August 07, 2024 |
$0.8 | $0.8 | June 28, 2024 | June 28, 2024 | July 31, 2024 | May 09, 2024 |
$0.8 | $0.8 | March 27, 2024 | March 29, 2024 | April 30, 2024 | February 07, 2024 |
$0.8 | $0.8 | December 28, 2023 | December 29, 2023 | January 31, 2024 | December 05, 2023 |
$0.75 | $0.75 | September 28, 2023 | September 29, 2023 | October 31, 2023 | August 02, 2023 |
$0.75 | $0.75 | June 29, 2023 | June 30, 2023 | July 31, 2023 | May 10, 2023 |
$0.75 | $0.75 | March 30, 2023 | March 31, 2023 | April 28, 2023 | February 09, 2023 |
$0.75 | $0.75 | December 29, 2022 | December 30, 2022 | January 31, 2023 | December 07, 2022 |
$0.695 | $0.695 | September 29, 2022 | September 30, 2022 | October 31, 2022 | August 03, 2022 |
$0.695 | $0.695 | June 29, 2022 | June 30, 2022 | July 29, 2022 | May 04, 2022 |
$0.695 | $0.695 | March 30, 2022 | March 31, 2022 | April 29, 2022 | February 02, 2022 |
$0.695 | $0.695 | December 30, 2021 | December 31, 2021 | January 31, 2022 | December 09, 2021 |
$0.63 | $0.63 | September 29, 2021 | September 30, 2021 | October 29, 2021 | August 04, 2021 |
$0.63 | $0.63 | June 29, 2021 | June 30, 2021 | July 30, 2021 | May 04, 2021 |
$0.63 | $0.63 | March 30, 2021 | March 31, 2021 | April 30, 2021 | February 02, 2021 |
$0.63 | $0.63 | December 30, 2020 | December 31, 2020 | January 29, 2021 | December 02, 2020 |
$0.575 | $0.575 | September 29, 2020 | September 30, 2020 | October 30, 2020 | July 30, 2020 |
$0.575 | $0.575 | June 29, 2020 | June 30, 2020 | July 31, 2020 | May 05, 2020 |
Peers: Medical - Devices
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() Boston Scientific Corporation
BSX
|
$152.94B | $103.77 | $1.10 | $52.73 | $4.36 |
![]() Abbott Laboratories
ABT
|
$222.39B | $128.22 | $3.30 | $33.35 | $4.94 |
![]() Medtronic plc
MDT
|
$116.19B | $90.61 | $2.77 | $28.80 | $2.11 |
![]() DexCom, Inc.
DXCM
|
$34.68B | $88.80 | $1.40 | $88.46 | $23.16 |
![]() Edwards Lifesciences Corporation
EW
|
$41.87B | $70.99 | $2.31 | $32.99 | $6.96 |
![]() |
$- | $ | $ | $ | $ |
![]() Zimmer Biomet Holdings, Inc.
ZBH
|
$20.63B | $103.65 | $0.00 | $0.00 | $0.00 |
![]() ZimVie Inc.
ZIMV
|
$382.80M | $13.87 | $-14.87 | $-1.19 | $1.15 |
![]() STERIS plc
STE
|
$22.25B | $225.44 | $3.83 | $57.73 | $3.46 |
![]() Smith & Nephew plc
SNN
|
$10.93B | $25.08 | $0.30 | $45.15 | $2.28 |
Related Metrics
Explore detailed financial metrics and analysis for SYK.